Edward Franek

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency

Paweł Płudowski, Elżbieta Karczmarewicz, Milan Bayer et al. · Endokrynologia Polska · 2013 · 521 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +17

Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study

Monika Puzianowska‐Kuźnicka, Magdalena Owczarz, Katarzyna Wieczorowska–Tobis et al. · Immunity & Ageing · 2016 · 439 citations · Full text

Education, Geriatric Medicine, Immunology +17